ABSTRACT

The aim of this study was to test whether poststroke oral administration of a small molecule p75 neurotrophin receptor (p75NTR) modulator (LM11A-31) can augment neuronal survival and improve recovery in a mouse model of stroke. Mice were administered LM11A-31 for up to 12 weeks, beginning 1 week after stroke. Metabolomic analysis revealed that after 2 weeks of daily treatment, mice that received LM11A-31 were distinct from vehicle-treated mice by principal component analysis and had higher levels of serotonin, acetylcholine, and dopamine in their ipsilateral hemisphere. LM11A-31 treatment also improved redox homeostasis by restoring reduced glutathione. It also offset a stroke-induced reduction in glycolysis by increasing acetyl-CoA. There was no effect on cytokine levels in the infarct. At 13 weeks after stroke, adaptive immune cell infiltration in the infarct was unchanged in LM11A-31–treated mice, indicating that LM11A-31 does not alter the chronic inflammatory response to stroke at the site of the infarct. However, LM11A-31–treated mice had less brain atrophy, neurodegeneration, tau pathology, and microglial activation in other regions of the ipsilateral hemisphere. These findings correlated with improved recovery of motor function on a ladder test, improved sensorimotor and cognitive abilities on a nest construction test, and less impulsivity in an open field test. These data support small molecule modulation of the p75NTR for preserving neuronal health and function during stroke recovery.

SIGNIFICANCE STATEMENT

The findings from this study introduce the p75 neurotrophin receptor as a novel small molecule target for promotion of stroke recovery. Given that LM11A-31 is in clinical trials as a potential therapy for Alzheimer’s disease, it could be considered as a candidate for assessment in stroke or vascular dementia studies.
used to restore cerebral blood flow in acute ischemic stroke; however, less than 20% of patients qualify for this type of reperfusion therapy, and it must be initiated within 24 hours of stroke onset (Rabinstein, 2020). In contrast, no pharmacologic therapies are available to enhance recovery in the days and weeks after stroke. This prompts the need to identify compounds commonly applied to, or in the pipeline for, the treatment of other neurologic disorders to determine if they can promote neural repair and recovery of cellular function after stroke. One such example is LM11A-31, a small molecule ligand for the p75 neurotrophin receptor (p75NTR). LM11A-31 is currently under Phase IIa clinical evaluation for the treatment of mild to moderate Alzheimer’s disease (AD) (ClinicalTrials.gov Identifier: NCT03069014).

p75NTR is expressed in basal forebrain cholinergic, cortical, hippocampal, noradrenergic, and other central nervous system neurons (Becker et al., 2018) that have critical roles in learning and memory, cognition, psychological wellbeing, and sensorimotor functions. It is a tumor necrosis factor family member receptor that recognizes neurotrophins, including nerve growth factor, neurotrophin-3, neurotrophin-4/5, and brain derived neurotrophic factor. Although once categorized as a death initiating receptor, it is now clear that it can also promote cell survival through phosphoinositide 3-kinase/protein kinase B and interleukin-1 receptor-associated kinase/nuclear factor-κB dependent signaling mechanisms (Longo and Massa, 2008). The balance of prosurvival versus proapoptotic signaling is determined by the availability of adaptor molecules, which is itself determined by cell type and contextual cues (Longo and Massa, 2008).

LM11A-31 specifically functions as a p75NTR ligand. This specificity is supported by multiple lines of evidence, including the rapid recruitment of the interleukin-1 receptor associated kinase p75NTR intracellular adaptor after treatment in vitro, the ability of LM11A-31 to block a p75NTR antibody from binding to the receptor, and conversely the ability of p75NTR antibodies to block LM11A-31 activity. It is also supported by loss of ligand signaling and function in p75NTR−/− neurons, nerve growth factor like promotion of p75NTR endocytosis, and no detectable effect of LM11A-31 on tropomysin receptor A (Longo and Massa, 2008, 2013). At nanomolar concentrations in vitro, LM11A-31 prevents neuronal death, promotes neurotrophic signaling, and inhibits neurodegenerative signaling through the p75NTR (Massa et al., 2006; Yang et al., 2008). Therefore, LM11A-31 functions as a p75NTR receptor modulator rather than a simple agonist or antagonist, switching p75NTR from neurodegenerative to neurotrophic signaling in neurons expressing p75NTR (Xie et al., 2019).

Importantly, LM11A-31 has shown therapeutic effects in multiple animal models of neurologic diseases, including post-traumatic brain injury (Shi et al., 2013), human immunodeficiency virus related dementia (Meeker et al., 2016; Fogle et al., 2021; Xie et al., 2021), contrusion spinal cord injury (Tep et al., 2013), Huntington’s disease (Simmons et al., 2016, 2021), and AD (Knowles et al., 2013; Nguyen et al., 2014; Simmons et al., 2014; Yang et al., 2020a). In AD, LM11A-31 has been shown to be efficacious in male and female mice and in two different mouse models of AD (Simmons et al., 2014). It has also been shown to reverse neuronal degeneration in late-stage AD pathology in transgenic mice (Knowles et al., 2009, 2013; Simmons et al., 2013; Nguyen et al., 2014; James et al., 2017). LM11A-31 is orally bioavailable and central nervous system penetrant, exerting maximal efficacy in the 25–50 mg/kg range (hydrochloride salt form), which at 50 mg/kg corresponds to a human equivalent dose of 284 mg for a 70 kg adult, per body surface area mouse to human conversion (Massa et al., 2006; Yang et al., 2008). LM11A-31 reaches and preferentially accumulates in the brain compared with blood (Knowles et al., 2013), which reduces the likelihood of systemic toxicity.

In light of the efficacy of LM11A-31 across a wide spectrum of neurologic diseases, its attractive pharmacokinetic properties, and the fact that it is currently undergoing clinical testing for the treatment of AD, we sought to determine whether LM11A-31 could protect neurons from the chronic sequelae of stroke that cause neurodegeneration in the weeks after stroke. We discovered in a mouse model of experimental stroke that daily oral administration of LM11A-31 can mitigate secondary neurodegeneration, increase neurotransmitter levels, and improve functional recovery. These findings correlated with changes in redox homeostasis and energy metabolism in the injured hemisphere, but no changes in inflammation within the infarct. Together, these data support the use of LM11A-31 for preserving neuronal health and function in patients recovering from stroke.

### Materials and Methods

#### Mice

All experiments used 17- to 18-month-old, male C57BL/6J (The Jackson Laboratory, Stock No: 000664) mice. All mice were given ad libitum access to food and water and were maintained in a 12-hour light/dark cycle in a temperature-controlled housing facility. In accordance with Stroke Therapy Academic Industry Roundtable (STAIR) recommendations (Lyden et al., 2021), mice from phase I (Cohort 1) were randomly allocated into treatment groups before the stroke/sham procedure. Additionally, mice from phase II (Cohort 2) were stroke and stratified into treatment groups based on day 2 poststroke ladder rung data. All dosing, behavioral experiments, imaging, and morphologic and biochemical analyses were performed with blinding relative to vehicle versus LM11A-31 treatment. All procedures met National Institutes of Health guidelines with the approval of the University of Arizona Institutional Animal Care and Use Committee.

#### Stroke and Sham Surgeries.

Distal middle cerebral artery occlusion with hypoxia (DH stroke) was performed as previously published (Doyle et al., 2012). Briefly, after anesthesia by isoflurane inhalation, the temporalis muscle was exposed by incision. The right middle cerebral artery (MCA) was identified and exposed using a microdrill on the skull. The meninges were cut, and the distal region of the MCA was cauterized. The incision was then closed using surgical glue. Directly after receiving the distal MCA occlusion, mice underwent hypoxia (95% oxygen and 91% nitrogen) for 45 minutes. Sham-operated mice underwent the same surgical steps, except for cauterization of the MCA. They were also given 95% oxygen and 91% nitrogen for 45 minutes immediately after surgery. Throughout the surgery and hypoxia, mouse core temperature was monitored and maintained at 37°C. The purpose of hypoxia in this model is to increase infarct size, as C57BL/6 mice that receive a distal middle cerebral artery occlusion without hypoxia have significantly smaller infarcts (Doyle et al., 2012). This stroke model results in a consistent infarct volume of approximately 25% of the ipsilateral hemisphere located in the somatosensory cortex and the M1 region of the motor cortex (Doyle et al., 2012; Nguyen et al., 2018).

Mice were euthanized at 3 and 13 weeks after surgery with isoflurane inhalation and exsanguination and were perfused intracardially with 0.9% saline without heparin.
Biosciences at >97% purity, as assessed by liquid chromatography/mass spectroscopy. LM11A-31 (31-; final dose: 50 mg/kg, hydrochloride salt form) was prepared in sterile water and administered by oral gavage. This dose is efficacious in both male and female mice, in two models of AD, and has high efficacy on mid- to late-stage AD progression (Knowles et al., 2013; Nguyen et al., 2014; Simmons et al., 2014). An equivalent volume (10 µl per gram of body weight) of sterile water was administered by oral gavage to vehicle- (veh) treated mice.

**Global Metabolic Profiling.** At 3 weeks after surgery, infarcts from stroke mice and the equivalent region of the cortex from sham-operated mice were resected and the remainder of the ipsilateral hemispheres were snap frozen and sent to Metabolon (Morrisville, NC) for processing and analysis (Ribbenstedt et al., 2018). At Metabolon, samples were prepared by first removing proteins and extracting small molecules and metabolites through a series of aqueous and organic extractions. The resulting extract was divided into 4 aliquots, each of which then underwent metabolic profiling. Two aliquots were profiled using reverse phase ultrahigh performance liquid chromatography/tandem mass spectrometry in acidic positive ion conditions, 1 aliquot in conditions optimized for more hydrophobic compounds, and the other in conditions optimized for more hydrophilic compounds. Another aliquot was profiled using ultrahigh performance liquid chromatography/tandem mass spectrometry in basic negative ion conditions, and the fourth aliquot using hydrophilic interaction ultra-performance liquid chromatography. Data extraction, compound identification, metabolite quantification, and data normalization were performed using Metabolon’s proprietary software. Quality control and curation procedures were used to remove artifacts, misassignments, and background noise (Choi et al., 2018).

**Multiplex Immunoassay.** At 3 weeks after surgery, infarcts from stroke mice and the equivalent region of the cortex from sham-operated mice were dissected and sonicated in ice-cold 0.1 M phosphate buffer saline containing 1% triton X-100 and 0.1% sodium deoxycholate, Protease Inhibitor Cocktail (1:100; Millipore Sigma), and Phosphatase Inhibitor Cocktail 2 (1:100; Millipore Sigma). After centrifugation, the total protein concentration of each supernatant was measured using a Direct Detect Infrared Spectrometer (Millipore Sigma). Cytokines/chemokines were then quantified by multiplex immunoassay using a high sensitivity mouse multiplex magnetic bead kit (Millipore Sigma) and performed according to the manufacturer’s recommendations (MILLIPLEX MAP Mouse Cytokine/Chemokine Magnetic Bead Panel-Immunochemistry Multiplex Assay, MCTOMAG-70K). Each lysate sample, standard, and quality control were measured in duplicate. Plates were read using a MAGPIX instrument (Luminex, Austin, TX), and results were analyzed using MILLIPLEX Analyst 5.1 software (Millipore Sigma). For these analyses that were below the lower limit of detection, the lower limit of detection values was used for data analysis. Concentrations of cytokines/chemokines were normalized to concentrations of total protein in the lysates.

**Processing Brain Tissue for Histology and Immunohistochemistry.** At 13 weeks after stroke, brains were postfixed in 4% paraformaldehyde for 24 hours, followed by cryopreservation in 30% sucrose. Frozen coronal sections (40 µm) were then taken through the entire brain using a freezing Microtome HM 450 sliding microtome (ThermoFisher Scientific), at an angle of 32° and a distance of 4 mm from the ventricles and the thickness of the primary somatosensory cortex was measured in 2 sections per mouse, at Bregma 1.18 mm and 1.94 mm below the level of Bregma 1.70 mm. The total percentage occupied by p-tau was computed using NIH Image J software (Media Cybernetics, Rockville, MD).

**Quantitative Analysis of Brain Atrophy.** A 2x objective was used to visualize brain atrophy after stroke. To measure brain atrophy, 2 sections per mouse, at Bregma –1.70 mm and –1.94 mm were analyzed for anatomic abnormalities via Nissl staining. The area of the lateral ventricles and the thickness of the primary somatosensory cortex, from the corpus callosum through layers I-VI of the cortex of each hemisphere, were manually traced for each section. The area of the ventricles and the thickness of the cortex were computed using NIH Image J software (Media Cybernetics, Rockville, MD).

**Quantitative Analysis of Neuronal Degeneration.** For quantitative analysis of Neun+ immunoreactivity, Neun+ immunolabeled neurons in the primary somatosensory cortex adjacent to the infarct, and in the area of axonal degeneration in thalamic white matter regions were measured in 2 sections for each mouse. Section 1 was at the level of Bregma +1.18 mm, and section 2 was at the level Bregma +0.74 mm. Using a 10× objective, 2 fields were randomly selected from the ipsilateral cortex and thalamus for each section. Corresponding fields were taken from the contralateral hemisphere. For measurement of cholinergic neurodegeneration, ChAT+ immunolabeled cholinergic somas and their neurites in the medial septum were imaged. The total amount of ChAT+ immunoreactivity in the medial septum was quantified in 2 sections for each mouse with section 1 at Bregma +1.18 mm, and section 2 at Bregma +0.50 mm. For measurement of TH+ fiber projections, 2 fields were randomly selected from the primary somatosensory cortex adjacent to the infarct using a 40× objective. Three sections were analyzed per mouse for a total of 6 fields per mouse between Bregma +1.18 mm and Bregma +0.74 mm. Corresponding fields were taken from the contralateral hemisphere. The percent area occupied by NeuN+, ChAT+, and TH+ staining in each region was computed using NIH Image J software.

**Quantitative Analysis of Tau Immunoreactivity.** AT8/p-tau+, immunoreactivity in the degenerating white matter tracts of the thalamus were visualized with a 10x objective. In this analysis, 3 sections that contained the thalamus were selected; section 1 contained the thalamus at Bregma –0.70 mm, section 2 contained the thalamus at Bregma –1.46 mm, and section 3 contained the thalamus at Bregma –2.18 mm for each mouse. The total percentage occupied by p-tau+ staining in the thalamus on each section was computed using NIH Image J software. Sections from amyloid precursor protein (APP) (Nguyen et al., 2014, 2018) mutant mice displaying both amyloid and tau pathologies were used as a positive control for the pTau+ staining with the AT8 antibody.

**Quantitation of CD68, B220/CD45R, and CD3e Immunoreactivity in the Stroke Infarct.** Immunoreactivity of CD68+, labeled microglia/macrophages, B220+ labeled B cells, and CD3e+ labeled T cells were visualized with an 10x objective and measured in the infarct using NIH Image J (Media Cybernetics, Rockville, MD).
Three to 6 sections were stitched from 3 to 4 fields to capture the entire infarct area between Bregma – 0.46 mm and Bregma – 1.94 mm per mouse.

Quantitation of CD68 and CD3e Immunoreactivity in White Matter Tracts of the Thalamus. CD68+ microglia and macrophages and CD3e+ T cells were visualized with a 10x objective and analyzed separately per mouse at Bregma –1.70 in the white matter tracts of the thalamus (area of axonal degeneration) after stroke surgery. Two nonoverlapping, adjacent fields were randomly selected from 2 sections per mouse for CD68+ quantification from each hemisphere of the thalamus at the reticular thalamus nucleus to the ventral posteromedial thalamus nucleus. One field (2 sections per mouse for a total of 2 fields) was taken for CD3e+ quantification at the same brain region. The percentage occupied by CD68+ or CD3e+ immunostaining was computed.

Ladder Rung Test. The ladder rung test was adapted from the ladder rung walking task (Rha et al., 2011; Doyle et al., 2012). The apparatus consisted of plexiglass rungs (10.16 cm length × 0.32 cm diameter) spaced at a constant distance of 0.64 cm apart, inserted between two plexiglass walls (0.64 cm width × 76.20 cm length × 15.24 cm height) and spaced 3.18 cm apart, providing a wide enough space for the animal to transverse the ladder. The apparatus was suspended 18 cm from the tabletop surface using blocks. The test was performed in a darkened room with a desk lamp illuminating the start zone to incentivize the animals to move across the ladder, and a small box was placed at the end zone. The mice were kept in a plastic chamber (9 cm × 8 cm × 14 cm) that was level with the plexiglass rungs at the start zone. As a mouse moved across the ladder, its steps were recorded from below, using a camera that slides along the surface of the testing table. Prior to presurgery testing, training was necessary to ensure that the animals were able to spontaneously traverse the apparatus. Eight training trials were required for animals to make an acceptable maximum number of limb placement errors (<10%–12%). Each mouse was tested once on each test day. The ladder apparatus was cleaned thoroughly with 10% ethanol and wiped dry between trials to minimize olfactory cues.

Nest Construction Test. Mice were transferred to individual testing cages with all environmental enrichment items contained (i.e., domes, tunnels) removed. One square (5 cm) piece of nestlet (Ancare, Bellmore, NY) made of pressed cotton batting, was placed in the same place of each test cage. Mice were provided with food and water. Testing was performed overnight, and images of nests built by the mice were captured the next morning. Nests were scored as follows on a scale of 1–5 based on how they were constructed: (i) nestlet was largely untouched (>90% remaining intact; 1 point); (ii) nestlet was partially torn up (50%–90% remaining intact; 2 points); (iii) nestlet was mostly shredded, but often there was no identifiable nest site (<50% of the nestlet remaining intact and >90% within a quarter of the cage floor area, i.e., the cotton was not gathered into a nest, but scattered about the cage; 3 points); (iv) an identifiable, but flat nest (>90% of the nestlet shredded and the material was gathered into a nest within a quarter of the cage floor area, but the nest was flat, with walls higher than the mouse’s body height around <50% of its circumference; 4 points); and (v) a near perfect nest (>90% of the nestlet shredded and shaped into a crater, with walls higher than the mouse’s body height around >50% of its circumference; 5 points). This nest construction scoring system is based on Deacon and colleagues’ protocol (Deacon, 2006). Two trained experimenters scored each nest, and their values were averaged.

Y-Maze Spontaneous Alternation Behavior Test. Mice were tested in a Y-shaped maze composed of beige acrylicitrile butadiene styrene (ABS) plastic and consisting of two symmetrical arms and one longer arm set at a 120° angle from each other (equal arms: 7.5 cm width × 37.0 cm length × 12.5 cm height; longer arm: 7.5 cm width × 42.0 cm length × 12.5 cm height). Mice were placed at the end of the longest arm of the maze, facing outward, and allowed to freely explore the 3 arms for 5 minutes. Over the course of multiple entries, mice normally exhibit a tendency to visit a new arm of the maze rather than visiting a recently visited arm. An entry was recorded when all four limbs of the mouse were within an arm of the maze. The number of arm entries and the number of triads were recorded and scored by the ANY-maze behavioral video tracking software (Stoelting, Wood Dale, IL), and the percentage of spontaneous alternation behavior (SAB) was calculated by the software. The Y-maze apparatus was cleaned with 10% ethanol and wiped dry between trials to minimize olfactory cues.

Novel Object Recognition Test. The novel object recognition (NOR) arena consisted of a white opaque box measuring 38.0 cm width × 48.0 cm length × 20.0 cm height made of ABS plastic. Mice were habituated to the NOR arena over the course of 2 days prior to testing day. During the first day of habituation, mice were placed with cage mates for 15 minutes in the NOR arena. The next day, each mouse was allowed to explore the arena alone for 15 minutes. On testing day, each mouse first underwent an “object familiarization phase,” during which they were placed in the arena with two identical objects located at different corners of the arena 5 cm from the walls. The objects consisted of children’s building blocks of different shapes and colors. Mice were habituated to the NOR arena over the course of 2 days prior to testing day. During the first day of habituation, mice were placed with cage mates for 15 minutes in the NOR arena. The next day, each mouse was allowed to explore the arena alone for 15 minutes. On testing day, each mouse first underwent an “object familiarization phase,” during which they were placed in the arena with two identical objects located in different corners of the arena approximately 5 cm from the walls. The objects were two wooden blocks with distinctive indentations, contours, and colors. Published studies confirmed no innate preference between objects. Mice were allowed to explore the arena and objects for 5 minutes. Object exploration was defined as contact with the object by the mouse’s nose within 2 cm of the object, which was recorded by ANY-maze behavioral video tracking software. Four hours after the object familiarization phase, each mouse underwent an “object recognition testing phase,” during which they were placed back in the arena with one of the objects they previously explored during the familiarization phase (the familiar object) and a novel object (NO). The object role (novel versus familiar) and position (left versus right) were balanced within each experimental group. Different sets of objects were used for each timepoint to control for biases from previously exposed objects. ANY-maze behavioral video tracking software was used to compute the time each mouse spent exploring each object. The recognition index was calculated as (NO Time)/(NO Time + familiar object Time) and expressed as a percentage by multiplying by 100. The NOR apparatus was cleaned with 10% ethanol between trials to minimize olfactory cues.

Open Field Testing. The open field (OF) test assesses exploratory habits in a relatively large novel environment. The OF apparatus consisted of a beige ABS plastic arena measuring 50 cm length × 50 cm width × 50 cm height. The arena was divided into 10 cm squares (grid). The center zone of the arena measured 30 cm length × 30 cm width. The periphery zone included all the squares along the edge of the arena and measured 8 cm width. The space between the center and periphery zones was considered the “dead” zone. Each mouse was placed into the arena and allowed to explore for 5 minutes. During these 5 minutes, ANY-maze software was used to track the
center of the animal’s body within the arena. The software then computed the number of entries and exits into each zone for each mouse. The OF apparatus was cleaned with 10% ethanol and wiped dry between trials to minimize olfactory cues.

**Power Analysis and Sample Size Calculations.** Sample sizes were determined by a priori power analysis with data from our pilot studies and previous published studies (Nguyen et al., 2014, 2016, 2018). For the metabolomics and multiplex immunoassay analyses (phase I of the study), according to the calculations, the minimum number of mice needed to attain statistical significance of $P < 0.05$ with an 80% probability was $n = 5$ mice/experimental group when we anticipated a ≥20% difference between experimental groups with an SD of 11%. For the behavioral studies (phase II), the minimum number of mice needed to attain statistical significance of $P < 0.05$ with an 80% probability was $n = 9$ mice/experimental group when we anticipated a ≥20% difference between experimental groups with an SD of 15%. Therefore, we included a total of 10 male mice in each experimental group to account for possible deaths due to age or surgery for behavior tests. All the mice used for behavior tests were also used for morphologic studies (phase II of the study), even though the minimum number of mice needed to attain statistical significance of $P < 0.05$ with an 80% probability was $n = 9$ mice/experimental group when we anticipated a ≥20% difference between experimental groups with an SD of 10% for this analysis.

**Statistics.** Data are presented as mean ±SD. Datasets containing 3 groups were analyzed using a one-way ANOVA, followed by post-hoc Newman-Keuls testing. Datasets containing 2 groups were evaluated by Student’s t test. Significance was set at $P < 0.05$. For all figures, *p is $< 0.05$, **p is $< 0.01$, ***p is $< 0.001$, and ****p is $< 0.0001$. The statistical summary of the metabolomics data are shown in Table 1. Metabolon’s proprietary Pathway Surveyor tool was used to identify key pathways significantly altered by stroke and LM11A-31 treatment.

**Results**

**Study design.** The goal of this study was to evaluate the therapeutic effect of a p75Trn small molecule ligand on recovery from stroke. To achieve this goal, the study was divided into two testing phases. For phase I (Fig. 1A, study design), mice were randomized and underwent stroke or sham surgery. A week after surgery, mice were orally administered LM11A-31 for 7 days per week, one dose per day, for 2 weeks, beginning 1 week after surgery (experimental groups: $n = 5$ for sham-veh, $n = 5$ for stroke-veh, and $n = 6$ for stroke-31). At 3 weeks after surgery, mice were euthanized, and their ipsilateral hemispheres were processed for histology and immunostaining. The remainder of their ipsilateral hemispheres was processed for metabolomics. The goal of phase I was to evaluate how LM11A-31 alters brain biochemistry and poststroke inflammation during treatment.

For phase II (Fig. 1B, study design), a separate cohort of mice underwent baseline ladder rung testing, and their scores were used to stratify mice into either LM11A-31 or vehicle treatment groups (experimental groups: $n = 10$ for stroke-veh, and $n = 10$ for stroke-31). Mice then underwent stroke surgery and were administered with either LM11A-31 or vehicle for 5 days per week, one dose per day, by oral administration for 12 weeks, beginning 1 week after surgery. The ladder rung test was repeated at 2 days, 2 weeks, 6 weeks, and 10 weeks after stroke surgery. During the 12th week of treatment, mice were tested on a panel of behavioral tests, including a nest construction test, a Y-maze SAB test, a NOR test, and an OF test. After 12 weeks of treatment (13 weeks poststroke), mice were euthanized, and their brains were processed for histology and immunostaining. The goal of phase II was to evaluate treatment efficacy of LM11A-31 in the context of stroke recovery.

**Phase I: Global Metabolic Profiling of LM11A-31-Treated Mice.** After 2 weeks of treatment (3 weeks post-stroke or sham surgery), global metabolic profiling of the ipsilateral hemispheres from the mice treated with LM11A-31 and vehicle returned measurements for 645 compounds. After log transformation and imputation of missing values with the minimum observed value for each compound, a three-way ANOVA was performed to identify the chemicals that were significantly different between experimental groups.

Among the mice that were treated with vehicle alone, 169 chemicals were present at different signal intensities in stroke-damaged compared with sham-operated mice. Among the mice that were treated with LM11A-31, 135 chemicals were present at different intensities in stroke-damaged compared with sham-operated mice. The least difference in metabolic profile, which equated to changes in 38 chemicals, was detected among mice that underwent sham surgery, between those treated with LM11A-31 and those treated with vehicle. However, the equivalent comparison among stroke-damaged mice showed 159 chemicals that were altered by treatment with LM11A-31. These data indicate that (i) there are substantial alterations in brain metabolism at 3 weeks after stroke; (ii) that treatment with LM11A-31 in sham-operated mice does not substantially alter brain metabolism; and (iii) that 2 weeks of LM11A-31 versus vehicle administration substantially alters chronic changes in brain metabolism induced by stroke.

**Principle component analysis (PCA) was used to visually assess the separation between the experimental groups (Fig. 2). There was both a separation along component 1 due to treatment (Fig. 2, B and C), and along component 2 due to stroke (Fig. 2, B and D). This analysis demonstrated that there was subclustering based on both compound treatment and disease state. A summary of the numbers of chemicals that achieved statistical significance ($P ≤ 0.05$), as well as whether they were significantly different between experimental groups.**

---

**Table 1**

<table>
<thead>
<tr>
<th>Group compared by ANOVA</th>
<th>Total biochemicals</th>
<th>$P &lt; 0.05$ Biochemicals ([(][)])</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>wt stroke veh</td>
<td>wt stroke LM11A-31</td>
</tr>
<tr>
<td></td>
<td>wt sham veh</td>
<td>wt sham LM11A-31</td>
</tr>
<tr>
<td></td>
<td>169</td>
<td>135</td>
</tr>
<tr>
<td></td>
<td>128/41</td>
<td>107/28</td>
</tr>
<tr>
<td></td>
<td></td>
<td>23/15</td>
</tr>
<tr>
<td></td>
<td></td>
<td>87/72</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
increased or decreased is shown in Table 1, and a full list of the metabolic changes are provided in Supplemental Tables 1 and 2.

Next, we used a pathway surveyor tool to evaluate which key pathways are altered by stroke and by LM11A-31 treatment after stroke. This finding revealed that LM11A-31 can mitigate stroke-induced decreases in the levels of multiple neurotransmitters, as well as stroke-induced changes in redox homeostasis and glucose metabolism. With regard to neurotransmitter levels, we found that after stroke, mice had lower levels of glutamate, serotonin, and acetylcholine in the ipsilateral hemisphere compared with mice that underwent sham surgery (Fig. 3, A–C). Treatment with LM11A-31 after stroke significantly increased the levels of each of these neurotransmitters, except for glutamate. Notably, levels of dopamine trended toward a significant reduction after stroke ($P = 0.1038$) and were also significantly increased by LM11A-31 treatment (Fig. 3D).

Regarding redox homeostasis, global metabolic profiling revealed that stroke compared with sham surgery resulted in a decrease in reduced glutathione (GSH) in the ipsilateral hemisphere. LM11A-31 restored GSH in stroke mice (Fig. 4, top graph). LM11A-31 also increased levels of oxidized glutathione (GSSG) (Fig. 4, bottom graph). These results indicate that LM11A-31 treatment increases the pool of GSH available to modulate chronic changes in redox homeostasis caused by stroke.

Regarding glucose homeostasis (glycolysis pathway shown in Fig. 5A), although levels of glucose were undetected, levels of pyruvate were reduced in the ipsilateral hemisphere of the mice that underwent stroke compared with sham surgery (Fig. 5B). This finding indicates that there is a reduction in glycolysis in the ipsilateral hemisphere at 3 weeks after stroke. There was also a trend toward a reduction in acetyl-CoA, the oxidative decarboxylation product of pyruvate (Fig. 5B). This finding is an indication that the reduction in glycolysis reduces the amount of acetyl-CoA available for the tricarboxylic acid cycle. Treatment with LM11A-31 after stroke increased levels of acetyl-CoA (Fig. 5B).

Treatment with LM11A-31 after stroke also altered the glycojenesis/glycogenolysis pathway (Fig. 5C). This finding is supported by increases in maltotetraose, maltotriose, and maltose in the ipsilateral hemispheres of the LM11A-31–treated mice compared with the vehicle-treated mice after stroke (Fig. 5D). Like glucose, glycogen was undetected, and so it is unclear whether these differences in intermediates are the result of increased glycogenolysis or increased glycogenesis. However, combined with the elevated level of acetyl-CoA seen in LM11A-31–treated mice compared with vehicle-treated mice after stroke, these findings provide evidence that LM11A-31 treatment increases glycogenolysis, thereby increasing the amount of glucose available for acetyl-CoA generation.

Acetyl-CoA can also be generated by beta oxidation of long-chain fatty acids. To determine whether the increase in acetyl-CoA was the result of increased fatty acid oxidation, we evaluated whether LM11A-31 treatment after stroke increased the levels of carnitine and acetyl-carnitine, key metabolites required for the generation of acetyl-CoA by beta oxidation.
Although levels of carnitine and acetyl-carnitine were increased by stroke, they were not further increased by LM11A-31 treatment after stroke (Supplemental Tables 1 and 2). This result indicates that the increase in acetyl-CoA levels in response to LM11A-31 treatment after stroke is unlikely due to an increase in the beta oxidation of long-chain fatty acids.

Phase I: Evaluation of Cytokine/Chemokine Levels in the Infarct in LM11A-31-Treated Mice. We have previously provided evidence that stroke infarcts are sites of chronic inflammation (Doyle et al., 2015; Nguyen et al., 2016; Zbesko et al., 2018). To determine whether LM11A-31 has an effect on chronic inflammation in the infarct, we used a multiplex immunoassay to measure cytokines/chemokines within the...
infarcts of phase I mice and tissue from the equivalent region of the cortex from sham-operated mice. Analyses of interest included granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, interferon-γ, interleukin (IL)-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17, interferon-induced protein-10 (IP-10), keratinocytes-derived chemokine, monocyte chemoattractant protein-1, macrophage inflammatory protein-1α, macrophage inflammatory protein 1β (MIP-1β), macrophage inflammatory protein 2α (MIP-2α), regulated on activation normal T cell expressed and secreted (RANTES), and tumor necrosis factor-α. Out of these 25 cytokines/chemokines, only MIP-2α, IP-10, RANTES, and MIP-1α were increased in the infarct site at 3 weeks after stroke when compared with tissue from the equivalent hemisphere of sham-operated mice. LM11A-31 did not alter the levels of these cytokines/chemokines (Fig. 6). These data indicate that two weeks of LM11A-31 treatment does not ameliorate or exacerbate inflammation within the infarct site at 3 weeks after stroke.

**Phase II:** Evaluation of LM11A-31 on Peripheral Immune Cell Infiltration in the Infarct and Area of Axonal Degeneration. The goal of phase II was to evaluate the efficacy of LM11A-31 at ameliorating chronic neuropathology and neurodegeneration when treatment is initiated one week after stroke and after 12 weeks of daily dosing. The impact of LM11A-31 on inflammation in the infarct was determined by immunostaining of CD68+ microglia/macrophages, B220+ B cells, and CD3ε+ T cells at the site of the infarct. Percent area occupied by CD68+, B220+, and CD3ε+ immunostaining revealed that LM11A-31 treatment after stroke did not alter macrophage, B lymphocyte, or T lymphocyte cell infiltration into the infarct at 13 weeks (Fig. 7A–C).

We previously reported that in the weeks after stroke, CD3ε+ T cells are not only present in the infarct, but are also present in the thalamus, striatum, and internal capsule in the ipsilateral hemisphere (Doyle et al., 2015). These are locations of degenerating axons that project from the sensorimotor cortex, which is the cortical region infarcted in the DH stroke model. Treatment with LM11A-31 did not affect T cell infiltration into the thalamic white matter tracts of the area of axonal degeneration (Fig. 7D).

**Phase II:** Evaluation of the Impact of LM11A-31 on Secondary Neurodegeneration. Stroke causes delayed ipsilateral cortical atrophy and tissue thinning in 3- to 5-month-old C57BL/6 mice at 8 weeks poststroke (Nguyen et al., 2018). This atrophy is more pronounced and results in enlargement of the ipsilateral lateral ventricle in 18-month-old mice (Nguyen et al., 2018). Therefore, we next sought to determine whether brain atrophy caused by stroke can be prevented or reduced by treatment with LM11A-31. As shown in the representative images, stroked mice that were treated with LM11A-31 demonstrated a significant reduction in the degree of poststroke ventricular enlargement compared with those treated with vehicle (Fig. 8A). Additionally, vehicle-treated mice had significantly thinner ipsilateral primary somatosensory cortices compared with the contralateral cortices, and the equivalent cortices of LM11A-31–treated mice after stroke (Fig. 8B). These data demonstrate that LM11A-31 can ameliorate atrophy of the ipsilateral hemisphere after stroke.

Stroke-induced cortical atrophy correlates with neurodegeneration, as demonstrated by a reduction of neuronal nuclei marker, NeuN+, in the peri-infarct cortex of mice after stroke (Chung et al., 2018; Zbesko et al., 2018). As depicted in the representative images and quantification of stroked mice treated with LM11A-31 compared with vehicle, LM11A-31 treatment attenuated this reduction in NeuN+ immunoreactivity in the ipsilateral hemisphere (Fig. 8C, top images). Specifically, there was a reduction in NeuN+ expression in the ipsilateral compared with the contralateral hemisphere of the stroked mice, and LM11A-31 administration resulted in a preservation of NeuN+ immunoreactivity (Fig. 8C, bottom graphs). These data demonstrate that LM11A-31 can decrease the loss of NeuN+ immunoreactivity that occurs in the ipsilateral hemisphere in aged mice after stroke.

Most of the cerebral cortex, such as the prefrontal and the motor cortices, along with the somatosensory cortex, are connected to basal forebrain cholinergic neurons (Wu et al., 2014; Gielow and Zaborszky, 2017). Brain regions with synaptic connections to ischemic regions can undergo transneuronal degeneration after stroke (Zhang et al., 2012; Chang et al., 2016), and previously we observed approximately 30% less ChAT+ staining in the medial septum of the basal forebrain of 18-month-old C57BL/6 mice at 8 weeks poststroke compared with sham surgery (Nguyen et al., 2018). In the present study, there was significantly more ChAT+ immunoreactivity in the
Fig. 5. LM11A-31 altered glucose metabolism after stroke. (A) The glucose metabolism pathway or glycolysis. (B) Compared with sham-operated mice, stroked mice had significantly lower levels of pyruvate (top graph) in their brains and showed a trend toward lower levels of acetyl-CoA ($P = 0.0625$; bottom graph). Although 2 weeks of LM11A-31 (-31) treatment did not significantly increase pyruvate levels compared with veh treatment, it did significantly increase levels of acetyl-CoA compared with vehicle treatment. (C) Glycogenolysis/glycogenesis. (D) Although not altered by stroke, maltotetraose (top graph), maltotriose (middle graph), and maltose (bottom graph) were all increased after LM11A-31 treatment. This suggests that an increase in glycogenolysis may be the mechanism by which LM11A-31 increased acetyl-CoA after stroke. Group sizes: $n = 5$ sham-veh, $n = 5$ stroke-veh, $n = 6$ stroke-31. Data represent mean ±SD. *$P < 0.05$ and **$P < 0.01$. 
medial septum of the mice treated with LM11A-31 compared with mice administered vehicle (Fig. 8D).

Although primarily expressed in basal forebrain cholinergic neurons and pyramidal cortical and hippocampal neurons (Mufson and Kordower, 1992; Miller and Pitts, 2000; Dougherty and Milner, 1999; Zagrebelsky et al., 2005), p75NTR is also present in neurons of the raphe nuclei, reticular formation, and locus coeruleus (noradrenergic neurons that contribute to the regulation of mood and behavioral states). TH+ neurites of noradrenergic neurons in the rostral portion of the locus coeruleus innervate hippocampal and cortical areas and are markedly affected in and correlate with severity of cognitive decline (Grudzien et al., 2007) in AD and other neurodegenerative diseases, such as Down syndrome, Parkinson's disease, and Huntington's disease (Iversen et al., 1983; Mann, 1988; Zweig et al., 1992; Zarow et al., 2003). To determine whether stroke results in a loss of TH+ terminals innervating the peri-infarct cortical region, the density of TH+ labeled projections fibers in the ipsilateral and contralateral cortex was quantified. As shown in Fig. 8E (top images), TH+ projection fibers appeared diminished in density within the ipsilateral primary somatosensory cortex, adjacent to the infarct, compared with the contralateral cortex in the stroked mice. There was a significant decrease in TH+ expression in the ipsilateral compared with the contralateral hemisphere of the stroked mice, and LM11A-31 administration did not attenuate this reduction (Fig. 8E, bottom graph). Together, these data provide evidence that LM11A-31 can reduce brain atrophy and preserve NeuN+ and ChAT+ immunoreactivity after stroke but is less effective at preventing the loss of TH+ projection fibers.

Fig. 6. LM11A-31 did not alter cytokine levels in the infarct. (A) Out of 25 cytokines measured by multiplex immunoassay, only MIP-2α, IP-10, RANTES, and MIP-1β were significantly increased in the infarct at 3 weeks after stroke compared with sham surgery. Treatment with LM11A-31 for 2 weeks, beginning 1 week after stroke did not significantly alter the levels of these cytokines. Group sizes: n = 5 sham-veh, n = 5 stroke-veh, n = 6 stroke-31. Data represent mean ±SD. *P < 0.05, **P < 0.01, and ***P < 0.001.

Fig. 7. LM11A-31 did not alter immune cell infiltration in the infarct or T cell infiltration in the area of axonal degeneration. (A) Representative images and quantification of CD68 immunolabeled microglia and macrophages in the infarcts of mice given veh or LM11A-31 (-31) for 12 weeks, starting 1 week poststroke. Panels (i) and (ii) show the method of thresholding used to measure the % area covered by cellular CD68+ immunostaining. Stroked mice given vehicle and stroked mice given LM11A-31 displayed similar CD68+ immunoreactivity; quantification revealed no significant differences between these treatment groups. (B) B220+ immunolabeled B cells and (C) CD3e+ immunolabeled T cells in the infarcts of mice given vehicle or LM11A-31 for 12 weeks, starting 1 week poststroke. Stroked mice given vehicle and stroked mice given LM11A-31 also displayed similar B220+ and CD3e+ immunoreactivity; quantification revealed no significant differences between mice treated with either agent. (D) Representative images of CD3e+ immunolabeled T cells in white matter tracts projecting from the infarct area. There was no difference in CD3e+ immunoreactivity in stroked mice given vehicle or LM11A-31 in this area of axonal degeneration. Scale bars, 125 μm. Group sizes: n = 10 stroke-veh, n = 10 stroke-31. Data represent mean ±SD.
Phase II: Evaluation of the Effect of LM11A-31 on Microglial Activation and Tau Hyperphosphorylation. Ser202 and Thr205, the epitopes recognized by the antibody AT8 when they are phosphorylated, are among the tau residues that contribute to the pathologic conformations of p-tau (Jeganathan et al., 2008). Previously, we reported that 18-month-old stroked mice develop tau pathology in areas of degenerating white matter tracts after stroke (Nguyen et al.,...
Further, we have shown that excessive levels of p-tau+ staining are reduced in APP mutant mice after LM11A-31 treatment. Consequently, we determined whether LM11A-31 reduces p-tau accumulation in degenerating white matter tracts after stroke. As seen in Fig. 9A (top images), quantitation revealed that (i) the ipsilateral hemisphere contained more p-tau deposits than the contralateral hemisphere in the stroked mice and (ii) treatment with LM11A-31, and not vehicle, attenuated this p-tau burden within the ipsilateral hemisphere of stroked mice (Fig. 9A, bottom right graph). A representative image from sections of APP mutant mice served as a p-tau/AT8 staining positive control (Fig. 9A, bottom left image).

There is evidence for microglial activation in the proximity of tau deposits and for the interplay of tau pathology and inflammatory cascades (Perea et al., 2020). Stroked mice exhibited numerous CD68+ immunoreactive cells, which displayed an activated microglia morphology (large cell bodies and bushy, thick processes) in the ipsilateral white matter tracks, and a more typical resting morphology (small cell body with long branching processes) in the contralateral white matter tracks. In mice that underwent stroke, LM11A-31 administration decreased the burden of activated microglia (Fig. 9B, top images). Specifically, quantification of the area occupied by CD68+ labeled microglia/macrophages revealed significantly more CD68+ staining in the white matter tracks of the ipsilateral compared with the contralateral hemisphere of the stroked mice (Fig. 9B, bottom graph). However, after stroke, LM11A-31–treated mice had less CD68+ staining than vehicle-treated mice (Fig. 9B, bottom graph). These findings demonstrate that LM11A-31 reduces microglial activation in thalamic white matter tracks in aged mice after stroke.

**Phase II: Evaluation of LM11A-31 on Recovery after Stroke.** Given the protective effects of LM11A-31 against brain atrophy, neurodegeneration, and loss of critical neurotransmitters, LM11A-31 was evaluated for its ability to improve recovery after stroke. Motor recovery was assessed by gait using the horizontal ladder rung test (Doyle et al., 2012). Previously, after DH stroke, C57BL/6 mice at 5 months of age displayed a motor impairment of the front limb contralateral to the stroke starting at day 1, which continues until 2 weeks postsurgery (Doyle et al., 2012).

As expected, 2 days after stroke, performance on the ladder rung test was impaired, which localized to the contralateral (left) front limb compared with naïve mice at baseline or presurgery (Fig. 10A, left images: screenshots of video recordings to demonstrate a correct foot placement and two different types of foot fault: an inability to grip the ladder rung with the front paw and a foot slip). Scores from day 2 were used to stratify the mice into the LM11A-31 and vehicle treatment groups (Fig. 10A, middle graphs: stratification method). At 2 weeks, 6 weeks, and 10 weeks after stroke, LM11A-31–treated mice performed better than vehicle-treated mice on the ladder rung test, as measured by percent correct foot placement (Fig. 10A, left graphs).

Building nests is an innate and spontaneous mouse behavior, and nest construction can be assessed and used as a test for psychiatric disturbances that suggest a lack of motivation, anxiety, and obsessive compulsive behaviors, or pain (Jirkof, 2014). Typically, mice will make nests achieving scores between 3.5 and 4.5, leaving 0.5 g of nestlets unshredded. Mice with hippocampal lesions achieve a median score of 2.0 (Deacon, 2006), which is in line with the score of our mice at 12 weeks after stroke (Fig. 10B, left images). However, compared with treatment with vehicle alone, treatment with
LM11A-31 significantly improved the performance of mice on the nest construction test after stroke (Fig. 10B, right graph).

The Y-maze was then used to test SAB. This test is based on the innate interest of rodents to explore a new environment. SAB has been shown to be impaired in AD, and Knowles et al. (2013) have demonstrated that LM11A-31 attenuates behavioral deficits on a Y-maze (Faizi et al., 2012; Knowles et al., 2013). A naive or “normal” C57BL/6 mouse would typically score approximately 65%–70% SAB (Faizi et al., 2012; Knowles et al., 2013). However, after stroke, we did not detect a difference in SAB between stroked mice given LM11A-31 and those given vehicle (Fig. 10C).

NOR is a form of explicit memory known to be impaired in AD. The NOR test was used to evaluate whether LM11A-31 affects AD associated cognitive deficits in the stroke model. After stroke, there was no difference between stroked mice given LM11A-31 or vehicle; both experimental groups spent the same amount of time exploring a novel object relative to a familiar object (Fig. 10D).

The OF test provides a measure of anxiety and impulsivity. In a similar test of the anxiety-impulsivity spectrum, the light-dark transition test, aged, stroked mice display more impulsive risk-taking behavior (Nguyen et al., 2018). Here, we found a difference between stroked mice treated with LM11A-31 and those administered vehicle. Compared with vehicle-treated mice, LM11A-31–treated mice entered the open center zone significantly less than the open zone around the perimeter. The vehicle-treated mice displayed less cautious behavior, entering the center zone with greater frequency (Fig. 10E).

This provides evidence that treatment with LM11A-31 mitigates impulsive behavior in stroked mice. Together these data demonstrate that LM11A-31 can promote motor recovery, restore overall well-being, and mitigate impulsive like behavior in aged mice after stroke.

**Discussion**

In this study, we asked whether LM11A-31, a small molecule modulator of p75NTR signaling, could be used as a treatment of inhibiting neuronal degeneration and thereby preserve neuronal health and function after stroke. Our rationale was that decreases in the ratio of neurotrophic versus neurodegenerative signaling play a critical role in other neurodegenerative diseases, such as AD, and studies using mouse models of AD have found therapeutic benefits from treatments targeting p75NTR (Yang et al., 2008; Nguyen et al., 2014). LM11A-31 and its modulation of p75NTR signaling targets ubiquitous pathways and molecules shared among stroke and AD; for example, it can inhibit degenerative signaling via the tau kinases glycogen synthase kinase 3β, calpain, cyclin dependent kinase 5, c-jun, and p38, and promote survival signaling via Akt strain transforming (RAC alpha serine/threonine-protein kinase) and CREB.

Furthermore, there is evidence that pharmacological modulation of Trk, p75NTR, and nerve growth factor may prevent memory impairment in a rat model of global ischemia (Chourcy et al., 2019) and that neurotrophins, such as brain derived neurotrophic factor, may have therapeutic potential in protection against neurodegeneration and recovery from stroke and traumatic brain injury (Houlton et al., 2019). After stroke, the
expression of both pro-apoptotic and anti-apoptotic signaling molecules and transcription factors that are modulated by LM11A-31 are also upregulated in the ischemic penumbra (Yang et al., 2008; Nguyen et al., 2014; Simmons et al., 2016; Uzdensky, 2019; Yang et al., 2020a).

In the first phase of our study, we found that aged C57BL/6 male mice exhibit changes in brain metabolism after stroke that were attenuated after 2 weeks of oral administration of LM11A-31. To ensure we were evaluating the impact of LM11A-31 on stroke recovery rather than on infarct size, treatment was delayed until 1 week after stroke. One of the most striking changes was in the levels of several neurotransmitters. Stroke induced significant decreases in levels of the neurotransmitter’s glutamate, serotonin, and acetylcholine and a trend toward a reduction in dopamine. However, the decreases in serotonin and acetylcholine were not seen in the LM11A-31–treated stroked mice, which had significantly higher levels of these neurotransmitters than stroked mice treated with vehicle alone. LM11A-31–treated stroked mice also had significantly higher levels of dopamine than stroked mice treated with vehicle alone.

Serotonin’s biologic function is pleiotropic, as it modulates mood, cognition, reward, and learning and memory (Bacque-Cazenave et al., 2020). Acetylcholine is equally important, playing a role in attention, motivation, arousal, and memory (Sofuoglu and Mooney, 2009). The stroke induced reduction in levels of these essential neurotransmitters may impede proper signaling and thereby affect cognition, well-being, motor function, and psychologic health. The preservation of the levels of these neurotransmitters and the increase in the levels of dopamine in response to LM11A-31 treatment suggests a broad improvement in neuronal health and function after stroke.

In further support of this improvement, treatment with LM11A-31 for 12 weeks, with administration again delayed until 1 week after stroke, resulted in the preservation of brain volume and prevented loss of NeuN+ immunoreactivity. Atrophy of the brain likely results from progressive degeneration of neurons, and the loss of these neurons likely impedes recovery and contributes to the manifestation of dementia after stroke in some patients.

LM11A-31 may preserve and optimize the function of some neurons better than others, as suggested by our finding that LM11A-31 reduced the loss of ChAT+ immunostaining, but not TH+ immunostaining after stroke. This differential preservation may be explained by varying densities of p75NTR within the cell membranes of different neuronal subtypes; cholinergic neurons are rich in p75NTR and thus may bind more LM11A-31. Attesting to the protective effect of LM11A-31 on cholinergic neurons, other studies have found that treatment with LM11A-31 attenuates cholinergic degeneration in AD mouse models (Knowles et al., 2013; Nguyen et al., 2014; Simmons et al., 2014) and more recently that it suppresses age-related basal forebrain cholinergic neuronal degeneration (Xie et al., 2019).

Importantly, in conjunction with its effect on neuropathology after stroke, LM11A-31 also significantly attenuated impairments in motor function on the ladder rung test and significantly improved an activity of daily living in mice, as assessed by the nest construction test. Although the motor deficit induced by the stroke may have affected the ability of the mice to form nests, the improvement in nest building behavior nevertheless demonstrates that LM11A-31 treatment enhanced the ability of the mice to perform an innate behavior associated with their quality of living. LM11A-31 also significantly lessened stroke-induced impulsive behavior in the open field test. Notably, in the open field test, the vehicle-treated mice entered the center zone of the open field arena with greater frequency than the LM11A-31–treated mice. This suggests that their motor disability was not a confound for this test. Together, our data show that the administration of a p75NTR ligand increases neurotransmitter levels, reduces chronic stroke neuropathology, and improves recovery after stroke.

With regard to the mechanisms by which LM11A-31 improved stroke outcome, although LM11A-31 did not affect inflammation in the infarct, it did attenuate deficits in redox homeostasis after stroke by increasing the pool of reduced glutathione available to combat oxidative stress. Furthermore, treatment with LM11A-31 resulted in higher levels of acetyl CoA after stroke, suggesting LM11A-31 mitigated a stroke-induced reduction in glycolysis. Although our data do not reveal the mechanism by which acetyl CuA levels were increased by LM11A-31 treatment, an increase in several key metabolites in the glycogen pathway suggest that it may be via glycolgenolysis. However, further investigation into chronic changes in energy metabolism after stroke and how LM11A-31 treatment affects these changes is required.

We also determined that LM11A-31 treatment attenuated the accumulation of hyperphosphorylated tau in degenerating thalamic white matter tracts of aged mice after stroke. This finding is consistent with the demonstrated ability of LM11A-31 to inhibit the tau kinases glycogen synthase kinase 3 beta, calpain, cyclin dependent kinase 5, c-jun, and mitogen-activated protein kinase p38 (Yang et al., 2008; Nguyen et al., 2014; Yang et al., 2020b). Moreover, there is evidence for microglial activation in the proximity of tau deposits and for an interplay between tau pathology and inflammatory cascades (Perea et al., 2020). Previous studies have found that LM11A-31 can attenuate increased microglial activation in APP mutant mice with amyloidβ/42 and p-tau deposition (Nguyen et al., 2014). In line with this evidence, we observed that LM11A-31 administration decreased microglial activation in the thalamic white matter tracts of aged mice after stroke.

This study was designed with particular attention to STAIR recommendations (Lyden et al., 2021). Experiments were performed and analyzed in a randomized and blinded manner, we calculated the sample size based on a power analysis prior to the start of the study, and we considered the best route of administration for LM11A-31, which is oral delivery. We also chose a clinically useful therapeutic window by delaying treatment by 1 week and selected an appropriate stroke model for evaluating poststroke recovery rather than acute neuroprotection. However, there are further STAIR recommendations that should be followed prior to implementation of clinical testing. For example, follow-up studies are necessary to determine if LM11A-31 can also improve recovery in a stroke model where there is recanalization and reperfusion to emulate patients treated with tissue plasminogen activator and mechanical thrombectomy. LM11A-31 should also be tested by a second laboratory, in an alternative mouse strain (e.g., BALB/c mice), in a second species (e.g., rats), and in models that also feature common stroke comorbidities. It also needs to be ascertained if LM11A-31 is similarly effective in female mice. However, with regard to sex, LM11A-31 is similarly effective at reversing pathology in males and females in a
mouse model of AD (Simmons et al., 2014), protects against neurodegeneration in both male and female human immunodeficiency virus gp120 transgenic mice (Xie et al., 2021), and also protects against cisplatin-induced peripheral neuropathy in both male and female mice (Friesland et al., 2014). Therefore, a sex difference is not expected.

A limitation of this study is that the precise mechanism by which LM11A-31 reduced brain atrophy, preserved NeuN+ and ChAT+ immunoreactivity, and improved recovery after stroke is unclear. In AD, LM11A-31 prevents neuronal death, promotes neurotrophin signaling, and inhibits neurodegenerative signaling through the p75NTR. Although there are distinct differences between stroke and AD, the loss of neurotrophic support in the brain is a fundamental neurodegenerative mechanism common to both diseases. However, follow-up studies using p75NTR conditional knockout mice are necessary to determine the role of LM11A-31/p75NTR signaling in cholinergic and other specific neuronal subpopulations after stroke.

In conclusion, the findings of this study support a promising role for p75NTR as an effective target in the treatment of stroke beyond the acute setting, for which our current treatment options are extremely limited. Furthermore, because LM11A-31 has already reached phase IIa of clinical testing as a therapy for AD, once the STAIR recommendations for preclinical testing have been fulfilled, it could rapidly move to clinical trials in patients suffering from stroke and from patients suffering from AD and stroke.

Acknowledgments

The authors are grateful to Metabolon for their help with design, data acquisition, and data analysis of the metabolic experiment.

Authorship Contributions


Contributed new reagents or analytic tools: Yang, Longo.

Performed data analysis: Nguyen, Crumpacker, Calderon, Morris, Son, Doyle.

Wrote or contributed to the writing of the manuscript: Nguyen, Schnellmann, Longo, Doyle.

References


Jirkof P (2014) Burrowing and nest building behavior as indicators of well-being in mice. Front Neurosci 8:22.


A limitation of this study is that the precise mechanism by which LM11A-31 reduced brain atrophy, preserved NeuN+ and ChAT+ immunoreactivity, and improved recovery after stroke is unclear. In AD, LM11A-31 prevents neuronal death, promotes neurotrophin signaling, and inhibits neurodegenerative signaling through the p75NTR. Although there are distinct differences between stroke and AD, the loss of neurotrophic support in the brain is a fundamental neurodegenerative mechanism common to both diseases. However, follow-up studies using p75NTR conditional knockout mice are necessary to determine the role of LM11A-31/p75NTR signaling in cholinergic and other specific neuronal subpopulations after stroke.

In conclusion, the findings of this study support a promising role for p75NTR as an effective target in the treatment of stroke beyond the acute setting, for which our current treatment options are extremely limited. Furthermore, because LM11A-31 has already reached phase IIa of clinical testing as a therapy for AD, once the STAIR recommendations for preclinical testing have been fulfilled, it could rapidly move to clinical trials in patients suffering from stroke and from patients suffering from AD and stroke.

Acknowledgments

The authors are grateful to Metabolon for their help with design, data acquisition, and data analysis of the metabolic experiment.

Authorship Contributions

Participated in research design: Nguyen, Longo, Doyle. Conducted experiments: Nguyen, Crumpacker, Calderon, Garcia, Zbesko, Frye, Gonzalez, Becktel, Tavern-Garcia, Morrison. Contributed new reagents or analytic tools: Yang, Longo. Performed data analysis: Nguyen, Crumpacker, Calderon, Morris, Son, Doyle. Wrote or contributed to the writing of the manuscript: Nguyen, Schnellmann, Longo, Doyle.

References


Chourey AM, Al-Shorbagy MY, Attia AS, and El-Abhar HS (2019) Pharmacological studies using p75NTR conditional knockout mice are necessary to determine the role of LM11A-31/p75NTR signaling in cholinergic and other specific neuronal subpopulations after stroke.

In conclusion, the findings of this study support a promising role for p75NTR as an effective target in the treatment of stroke beyond the acute setting, for which our current treatment options are extremely limited. Furthermore, because LM11A-31 has already reached phase IIa of clinical testing as a therapy for AD, once the STAIR recommendations for preclinical testing have been fulfilled, it could rapidly move to clinical trials in patients suffering from stroke and from patients suffering from AD and stroke.

Acknowledgments

The authors are grateful to Metabolon for their help with design, data acquisition, and data analysis of the metabolic experiment.

Authorship Contributions

Participated in research design: Nguyen, Longo, Doyle. Conducted experiments: Nguyen, Crumpacker, Calderon, Garcia, Zbesko, Frye, Gonzalez, Becktel, Tavern-Garcia, Morrison. Contributed new reagents or analytic tools: Yang, Longo. Performed data analysis: Nguyen, Crumpacker, Calderon, Morris, Son, Doyle. Wrote or contributed to the writing of the manuscript: Nguyen, Schnellmann, Longo, Doyle.

References


Address correspondence to: Dr. Kristian P. Doyle, University of Arizona, Tucson, 1656 E Mabel Street, Medical Research Building, Room 214, Tucson, AZ 85719. E-mail: doylekr@email.arizona.edu; or Dr. Thuy-Vi V. Nguyen, University of Arizona, Tucson, 1656 E Mabel Street, Medical Research Building, Room 215, Tucson, AZ 85719. E-mail: thuyviv@email.arizona.edu.